Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: An overview

Expert Opinion on Drug Delivery

Volumn 9, Issue 9, 2012, Pages 1147-1160

  Argoff, Charles E ^a   Chen, Cuiping ^b   Cowles, Verne E ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Pharmacokinetics Depomed Inc   (United States)

Author keywords

Efficacy; Gabapentin; Gastroretention; Oral drug delivery; Pharmacokinetics; Postherpetic neuralgia; Tolerability

Indexed keywords

GABAPENTIN; PREGABALIN;

AREA UNDER THE CURVE; BLOOD LEVEL; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IN VITRO STUDY; KIDNEY CLEARANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PREGNANCY TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH JUICE; STOMACH ULCER; TABLET;

AMINES; ANALGESICS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTESTINAL ABSORPTION; NEURALGIA, POSTHERPETIC; TABLETS;

EID: 84865333818     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.709231     Document Type: Review

References (41)

1. Mao J, Chen LL. Gabapentin in pain management. Anesth Analg 2000;91(3):680-7
2. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271(10):5768-76 (Pubitemid 26083915)
3. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 2008;105(9):3628-33 (Pubitemid 351723603)
4. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13(11):1153-69 (Pubitemid 44581463)
5. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
6. Rice AS, Maton S. Gabapentin in posterpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94(2):215-24 (Pubitemid 33016615)
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310 (Pubitemid 32804122)
8. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150(9):1881-4 (Pubitemid 20316533)
9. Johnson P, Becker L, Halpern R, et al. Use of opioid analgesics in patients with postherpetic neuralgia (PHN) first treated with gabapentin or pregabalin (Abstract presented at American Pain Society (APS), 31st Annual Scientific Meeting, May 16-19, 2012, Honolulu, HI.). J Pain 2012;13(4 Suppl):S70
10. Bockbrader HN. Clinical Pharmacokinetics of Gabapentin. Drugs of Today 1995;31(No. 8):613-19 (Pubitemid 26048983)
11. Kriel RL, Birnbaum AK, Cloyd JC, et al. Failure of absorption of gabapentin after rectal administration. Epilepsia 1997;38(11):1242-4 (Pubitemid 27481425)
12. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10(2):276-81 (Pubitemid 23041744)
13. Dave MH, Schulz N, Zecevic M, et al. Expression of heteromeric amino acid transporters along the murine intestine. J Physiol 2004;558(Pt 2):597-610 (Pubitemid 39117604)
14. Mason GR, Kahrilas PJ, Otterson MF, et al. The Digestive System, in The Digestive System. In: O'Leary JP, editor. The Physiologic Basis of Surgery. Willams and Wilkens; Baltimore: 1996. p. 406-40
15. Mochiki E, Kuwano H, Nakabayashi T, et al. Pyloric relaxation regulated via intramural neural pathway of the antrum. Dig Dis Sci 2001;46(11):2307-13 (Pubitemid 33042325)
16. Sarna SK, Otterson MR, Cowles VE, Telfor GL. Investigations of myogenic, neural and chemical control of small intestinal motor activity. In: Gregersen H, Jensen SL, Moody F, editors. Essentials of experimental surgery. Harwood Academic Publishers; Reading England: 1996. p. 39/1-39/21
17. Cowles VE, Nellans HN, Seifert TR, et al. Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. J Pharmacol Exp Ther 2000;293(3):1106-11 (Pubitemid 30417882)
18. Meyer JH. Motility of the stomach and gastroduocenal junction. In: Johnson LR, editor. Physiology of the gastrointestinal tract. Raven Press; New York, NY, USA: 1987. p. 613-29
19. Houghton LA, Read NW, Heddle R, et al. Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology 1988;94(6):1285-91
20. Munk JF, Gannaway RM, Hoare M, Johnson AG. Direct measurement of pyloric diameter and tone in man and its response to cholecystokinin. In: Duthie HL, editor. Gastrointestinal motility in health and disease. MTP; Lancaster: 1978. p. 349-59
21. Timmermans J, Moes AJ. The cutoff size for gastric emptying of dosage forms. J Pharm Sci 1993;82(8):854 (Pubitemid 23314097)
22. Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci 1994;83(1):18-24 (Pubitemid 24233723)
23. Cowles VE, Gusler G, Chen TF, et al. Gastric emptying and intestinal transit of gastroretentive tablets in the fed state: effect of meal content and tablet size. Gastroenterology 2004;126(Suppl 2):A489-90
24. Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003;20(6):459-97
25. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998;15(3):243-84 (Pubitemid 28366513)
26. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993;10(2):143-95 (Pubitemid 23198886)
27. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;63(3):235-59
28. Gusler G, Hou SYE, Connor AL, et al. Pharmacoscintigraphic evaluation of metformin ER in healthy volunteers. Pharm Sci 2003;5:S1
29. Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011;51(3):346-58.
30. Gordi T, Hou E, Sreeneeranj K, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008;30(5):909-16. Phase I study which compares the steady-state PK of G-GR with IR gabapentin. (Pubitemid 351799872)
31. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 2009;25(3):185-92. Phase II trial of G-GR vs. placebo, where a trend toward efficacy was demonstrated for the once-daily arm and no tolerability issues were identified.
32. Sang CN, Sathyanarayana R, Sweeney M. Once-daily gabapentin for the treatment of postherpetic neuralgia: results of a multicenter, randomized, double-blind, placebo controlled phase 3 study. Clin J Pain 2012; in press
33. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 2010;30(11):765-76. First Phase III study, where efficacy of G-GR did not meet the primary end point but demonstrated efficacy in several secondary end points, including a post hoc analysis that demonstrated efficacy in patients with more than 6 months of pain since resolution of the acute rash.
34. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60(8):1274-83 (Pubitemid 36460982)
35. Sabatowski R, Gálvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109(1-2):26-35 (Pubitemid 38479767)
36. van Seventer R, Feister HA, Young JP Jr, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22(2):375-84 (Pubitemid 44296762)
37. Oxman MN, Levin MJ, Johnson GR, et al. Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84
38. Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 2006;120(1-2):207-12 (Pubitemid 43077184)
39. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280(21):1837-42 (Pubitemid 28544424)
40. Irving G. The placebo response: relationship to outcomes in trials of postherpetic neuralgia. Clin Drug Investig 2010;30(11):739-48
41. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain 2008;138(3):479-83